Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phathom is a biopharmaceutical company focused on gastrointestinal (GI) diseases, and its filings offer detailed information on VOQUEZNA (vonoprazan) commercialization, clinical programs, and corporate activity.
Through current reports on Form 8-K, Phathom reports material events such as quarterly and interim financial results, clinical trial milestones, leadership changes, and key scientific publications. For example, the company has used Form 8-K to announce financial results for specific quarters, publication of additional analyses from the Phase 3 pHalcon-NERD-301 trial in Non-Erosive GERD, and initiation of the Phase 2 pHalcon-EoE-201 study in eosinophilic esophagitis.
Filings also document capital markets transactions, including underwritten public offerings of common stock and pre-funded warrants, and provide details on the intended use of proceeds for working capital, commercialization, and research and development expenses. Disclosures about executive appointments and compensation arrangements, such as the appointment of a Chief Financial and Business Officer, are likewise reported in 8-K filings.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the key points of lengthy filings, helping readers quickly understand topics such as operating performance, clinical trial updates, and corporate governance changes. Users can monitor real-time updates from EDGAR, review quarterly and annual reports when available, and examine current reports for insights into Phathom’s GI-focused business. This page serves as a central resource for investors and researchers who want to analyze PHAT’s official disclosures alongside concise AI-generated explanations.
Phathom Pharmaceuticals reported strong first-quarter 2026 growth driven by its VOQUEZNA franchise but remained unprofitable. Product revenue reached $58.3 million, up from $28.5 million a year earlier, as prescription volume and prescriber adoption increased, mainly for GERD indications.
Net loss narrowed to $30.4 million from $94.3 million, helped by higher gross profit and significantly lower selling, general and administrative expenses. Phathom ended March 31, 2026 with $180.9 million in cash and cash equivalents, while carrying $175.0 million of term debt and a $380.9 million revenue interest financing liability tied to vonoprazan sales.
Phathom Pharmaceuticals reported strong first quarter 2026 momentum as it continues its shift to gastrointestinal (GI) markets. Net product revenue reached $58.3 million, more than double the prior year’s first quarter, driven by growing VOQUEZNA prescriptions among GI specialists.
Gross profit was $46.3 million, and operating loss narrowed sharply to $15.5 million from $78.9 million a year earlier as total operating expenses fell to $61.8 million, with selling, general and administrative costs dropping to $54.0 million. On a non-GAAP basis, adjusted net loss improved to $14.7 million, or $0.18 per share.
Phathom ended March 31, 2026 with $180.9 million in cash and cash equivalents and continues to carry a stockholders’ deficit. Management reiterated full-year 2026 guidance and expects to achieve operating profitability beginning in the third quarter and for the full year 2026, and to reach cash flow positivity in 2027.
Phathom Pharmaceuticals, Inc. is soliciting proxies for its 2026 annual stockholder meeting, to be held virtually on May 19, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on March 23, 2026, when 79,430,117 common shares were outstanding, may vote.
Stockholders will vote on electing three Class I directors to terms ending at the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for 2026, and approving named executive officer compensation on a non-binding advisory “say‑on‑pay” basis. The proxy describes board composition, committee structures, director independence, director and committee retainers, equity grants, and significant stockholders’ ownership, as well as detailed voting procedures and the treatment of abstentions and broker non‑votes.
Phathom Pharmaceuticals, Inc. Schedule 13G filing reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander together beneficially hold 4,178,411 shares of common stock, representing 5.3% of the class as of 03/06/2026. The filing discloses shared voting and shared dispositive power over those 4,178,411 shares.
Phathom Pharmaceuticals director Asit Parikh reported gifting 80,000 shares of Common Stock. On March 10, 2026, he made two bona fide gift transfers of 40,000 shares each, with no cash consideration.
After these gifts, Parikh directly holds 10,500 shares and indirectly holds 120,500 shares through a trust for the benefit of his spouse, for which he serves as trustee. These are non-market, charitable-style transfers rather than open-market sales.
Phathom Pharmaceuticals Principal Accounting Officer Robert Charles Breedlove reported stock-based compensation activity in common stock. He received 13,000 restricted stock units and 2,790 performance stock units on February 27, 2026. The performance units relate to a grant from February 27, 2025 with performance criteria confirmed on February 27, 2026. To cover tax withholding on these awards, 964 shares tied to performance stock units and 414 shares tied to RSUs were surrendered back to the company at $12.56 per share. After these transactions, he directly holds 61,480 common shares and indirectly holds 6,945.4 shares through a 401(k) account.
Phathom Pharmaceuticals is a commercial-stage biopharma company focused on gastrointestinal diseases, built around vonoprazan, a potassium-competitive acid blocker marketed in the U.S. as VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK.
The products treat erosive and non-erosive GERD and Helicobacter pylori infection, with U.S. launches beginning in late 2023. The company reports higher 2025 revenues from VOQUEZNA products versus the prior year, driven by growing prescription volume and prescriber adoption, with most use in GERD. As of February 13, 2026, more than 1.1 million prescriptions have been filled and VOQUEZNA has commercial coverage for over 120 million, or more than 80%, of U.S. commercial lives.
Regulatory protection is a major asset: QIDP and new chemical entity status, plus an FDA-granted citizen petition, give all three VOQUEZNA products U.S. exclusivity through May 3, 2032. Phathom is also advancing a Phase 2 trial of vonoprazan in eosinophilic esophagitis and evaluating additional lifecycle, geographic and OTC opportunities, while facing competition from generic PPIs and emerging PCABs.
Phathom Pharmaceuticals reported strong revenue growth but continued losses for the fourth quarter and full year 2025. Net product revenue reached $57.6 million in the fourth quarter, up from $29.7 million a year earlier, and $175.1 million for 2025 versus $55.3 million in 2024.
Full-year operating expenses fell to $312.5 million from $324.7 million, and the GAAP net loss narrowed to $221.2 million from $334.3 million. Cash and cash equivalents were $130.0 million at December 31, 2025, compared with $297.3 million a year earlier, while total liabilities increased and stockholders’ deficit deepened.
Management highlighted VOQUEZNA commercial momentum, a sales force realignment, and a January financing followed by a term loan modification to reduce interest and extend maturity. The company stated that it is positioning for anticipated operating profitability in the third quarter 2026 and to reach cash flow positivity in 2027, supported by tighter expense discipline and revenue growth.
Phathom Pharmaceuticals’ chief legal officer and corporate secretary Anne Marie Cook reported equity compensation activity in company common stock. On February 10, 2026, she acquired 3,461 shares at $0 upon vesting of performance stock units granted on June 23, 2025 after performance criteria were met.
On the same date, 1,535 shares were disposed of at $12.82 to satisfy the issuer’s tax withholding obligation related to that vesting. After these transactions, Cook directly owned 88,660 shares, which include 1,722 shares previously acquired through the company’s employee stock purchase plan in January 2026.